Investigating the effect of saffron on the consciousness of stroke patients

Investigating the effectiveness of saffron medicine on the prognosis of ischemic CVA patients with NIHSS less than 15

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230715058781N1

Enrollment

Registered

2023-07-17

Start date

2023-09-23

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebrovascular accident. Cerebellar stroke syndrome

Interventions

Intervention 1: Intervention group: Including 37 patients who will receive 30 mg of saffron capsules from Duralife -Faran Chemi Pharmaceutical Company (15 mg twice a day) for 30 days orally in additio

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with ischemic stroke

Exclusion criteria

Exclusion criteria: Coagulation disorders

Design outcomes

Primary

Measure	Time frame
Level of consciousness. Timepoint: arrival; hospitalization time; while receiving medication. Method of measurement: Glasgow coma scale.	—

Secondary

Measure	Time frame
Length of hospitalization. Timepoint: The time of the patient's discharge from the hospital. Method of measurement: National Institutes Of Health Stroke Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayeh Mehrpour

Ghoum University of Medical Sciences

somayeh.mehrpour@gmail.com+98 25 3612 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026